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Single nucleotide polymorphisms (SNPs) of p53 rs1042522, MDM2 rs2279744 and p21 rs1801270, all in 
the p53 pathway, which plays a crucial role in DNA damage and genomic instability, were reported to 
be associated with cancer risk and pathologic characteristics. This case-control study was designed to 
analyse the association between these SNPs and retinoblastoma (RB) in a Chinese Han population. 
These SNPs in 168 RB patients and 185 adult controls were genotyped using genomic DNA from 
venous blood. No significant difference was observed in allele or genotypic frequencies of these 
SNPs between Chinese RB patients and controls (all P > 0.05). However, the rs1042522 GC genotype 
showed a protective effect against RB invasion, as demonstrated by event-free survival (HR = 0.53, 
P = 0.007 for GC versus GG/CC). This effect was significant for patients with a lag time >1 month 
and no pre-enucleation treatment (P = 0.007 and P = 0.010, respectively), indicating an interaction 
between p53 rs1042522 and clinical characteristics, including lag time and pre-enucleation treatment 
status. Thus, the rs1042522 SNP may be associated with RB invasion in the Han Chinese population; 
however, further large and functional studies are needed to assess the validity of this association.
Retinoblastoma (RB), a rare eye tumour observed in paediatric patients, is the most common intraoc-
ular malignancy among children worldwide1. Its global annual incidence is one case per 15,000–20,000 
newborns—an estimated 9,000 new cases every year2. Both germinal/heritable (40%) and non-germinal/
non-heritable RB (60%) originate in the primordial retinal cells and are predominantly initiated by 
biallelic inactivation of the RB1 gene1. The deletion of Rb family members leads to the compensatory 
up-regulation of the cyclin-dependent kinase inhibitor3 p21, which is the primary protein upregulated by 
p53 in response to DNA damage4. The p53 pathway, which is the master control system of the cell cycle, 
genome stability, and cell apoptosis, is controlled by a negative feedback loop in which p53 transcrip-
tionally activates MDM2, which in turn functions as a negative regulator by promoting the proteolytic 
degradation of p535. In addition to the loss of function of the RB1 gene, several other genes have been 
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shown to be dysregulated in RB cells6–8 through single nucleotide polymorphisms (SNPs) in p53 pathway 
genes and may influence RB cancer risk among other ethnic populations9–13, indicating that SNPs in the 
p53 pathway genes and RB1 gene mutations may coincide in RB.
The Arg to Pro change in codon 72 (also known as p.Arg72Pro, rs1042522 G > C) is the most 
frequently studied functional SNP in p53. Compared with the G allele, the C allele of rs1042522 in 
p53 reduces proapoptotic activity and ultimately mediates the attenuation of the p53 pathway in con-
cert with its induction of the MDM2 gene and other p53 targets14. An explanation of this diminished 
proapoptotic activity for the C allele is suggested to be a high affinity binding of the inhibitor of the 
apoptosis-stimulating protein of the p53 family15. Furthermore, the rs1042522 SNP modulates suscep-
tibility to several human cancers, including hereditary RB in an Italian population10. In addition, the 
G allele has been associated with increased tumour stage16–18 and higher invasive or metastatic risk of 
cancer19,20. For the MDM2 gene, the G allele of a naturally occurring SNP at position 309 in the MDM2 
promoter (also known as c.14 + 309T > G, rs2279744 T > G) has been shown to produce a higher-affinity 
DNA-binding site for Sp1, which leads to increased MDM2 mRNA and protein and thus increases the 
degradation of p53 and hinders p53-induced apoptosis21. Increased MDM2 expression is related to ele-
vated cancer risk in sporadic and hereditary malignancies and to an increased likelihood of distant 
metastases22, and rs2279744 in the MDM2 gene is also associated with RB development9–11. Overall, these 
data indicate a risk-modifying effect of p53 and MDM2 SNPs on cancer23,24 and an association of these 
SNPs with pathological tumour characteristics25,26.
p21 is the primary protein that is upregulated by activated p53 in response to DNA damage4; con-
versely, p21 acts as a negative regulator of p53 stability27. Moreover, MDM2 negatively regulates p21 pro-
tein stability via proteasome-mediated degradation28. Most studies have focused on the p21 SNP in codon 
31 (also known as p.Ser31Arg, rs1801270 C > A), which results in a non-synonymous serine-to-arginine 
substitution in the DNA-binding zinc finger motif of the protein29 and can lead to the failure of p21 to 
accumulate upon DNA damage, despite a normal p53 protein response30. Thus, this p21 SNP may affect 
the expression and activity of p21, thereby disturbing the p53 pathway activity and playing a role in the 
susceptibility to cancers31 including RB13.
Additionally, the p53 pathway targets pRB for degradation and controls the cell cycle and apoptosis in 
retinal cone precursor cells, from which the RB cell lineage originates32. Thus, the rs1042522, rs2279744, 
and rs1801270 SNPs in p53 pathway genes may affect the fate of RB. Previous studies have highlighted 
the contribution of the common functional SNPs rs1042522, rs2279744, and rs1801270 to RB cancer 
risk in non-Chinese populations9–13; however, to our knowledge, the association between these SNPs 
and RB invasion has not been reported. In the current study, for the first time, we genotyped these SNPs 
(rs1042522, rs2279744, and rs1801270) and evaluated their association with RB cancer risk and tumour 
invasion in a Chinese population.
Results
Study-population. This study was conducted on 168 RB patients and 185 cancer-free adult controls. 
The mean age of all patients at presentation was 20.0 ± 16.6 months, with a range from 1.0 to 118 months. 
No significant difference in gender was detected between the RB patients and the controls (P = 0.081). 
The clinical characteristics of the RB patients are summarised in Table 1. According to the International 
Classification of Retinoblastoma (ICRB), in the 168 patients, 131 eyes from 131 patients were enucleated, 
including 67 eyes (51.1%) in hazard group D and 64 eyes (48.9%) in hazard group E. Among enucleated 
patients, the percentage who received pre-enucleation treatment was higher in bilateral RB (78.9%) than 
in unilateral RB (5.4%) (P = 0.000), and a significantly negative correlation was observed between the 
age at presentation and lag time or pre-enucleation treatment (r = − 0.21, P = 0.018; r = − 0.25, P = 0.004, 
respectively). Histopathology reports were retrospectively staged for pTNM-staging characteristics, and 
re-examination of the histopathological findings by a second reviewer (R.C.) showed 100% concurrence 
regarding the grade of RB invasion. Of the 131 enucleated eyes, 37 (28.2%), 49 (37.4%), and 45 (34.4%) 
enucleated eyes showed no, moderate, and high invasion, respectively.
rs1042522, rs2279744, and rs1801270 SNPs and RB cancer risk. The p53 rs1042522, MDM2 
rs2279744, and p21 rs1801270 SNPs were clearly distinguished by matrix-assisted laser desorption/ioni-
sation time-of-flight (MALDI-TOF) mass spectrometry (MS), and the success rates of the genotype calls 
for these SNPs were 100%, 99.7%, and 100%, respectively. Representative spectral peak diagrams are 
depicted in Fig. 1. In the control group, the genotype distributions of the evaluated SNPs were consistent 
with Hardy-Weinberg equilibrium (HWE) (all P > 0.05, Table 2). As shown in Table 2, neither the minor 
allele frequencies (MAFs) nor the genotype frequencies of the three selected SNPs were significantly 
different between RB and control groups (all P > 0.05).
rs1042522, rs2279744, and rs1801270 SNPs and RB invasion. Briefly, the distributions of the 
analysed genotypes were not significantly associated with any clinical characteristics of the patients 
(see Supplementary Table S1), except for the distribution of rs1042522 genotypes in laterality and 
pre-enucleation treatment status (P = 0.001 and P = 0.013, respectively) and of rs2279744 genotypes 
in lag time (P = 0.007); we adjusted for these factors in the Cox regression model analysis. For the 
patients with enucleated eyes, the analyses revealed almost identical associations of the selected SNPs 
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with moderate and high invasion (see Supplementary Table S2). Therefore, the moderate and high inva-
sion groups were combined into one group.
As shown in Fig. 2, a significant association was observed only for the rs1042522 SNP. Relative to the 
combined homozygous genotypes (GG and CC) in an over-dominant genetic model, the heterozygous 
GC genotype of p53 rs1042522 was significantly associated with event-free survival (EFS) for RB invasion 
(P = 0.000, Fig. 2a-b). For the genotypic association analysis of p21 rs1801270 and MDM2 rs2279744, no 
significant association with EFS was observed (Fig. 2c-d).
The results of the multivariate analysis of EFS using the Cox proportional hazards model are pre-
sented in Table 3. Only the carriers of the p53 rs1042522 GC genotype exhibited a significantly decreased 
risk of RB invasion (HR = 0.53; 95% CI = 0.33–0.84; P = 0.007) after adjustment for age (≤ 12 or > 12 
months), gender (male or female), laterality (unilateral or bilateral), clinical predictors (whether pre-
sented), ICRB (group D or E), lag time (≤ 1 or > 1 month), and pre-enucleation treatment (adminis-
tered or not). Furthermore, a lag time greater than 1 month and no pre-enucleation treatment were also 
associated with a reduced risk of RB invasion based on multivariate analysis (HR = 0.10, 95% CI = 0.05–
0.24, P = 0.000, and HR = 0.02, 95% CI = 0.05–0.24, P = 0.000, respectively); a significant association 
was observed between age older than 12 months or bilateral eyes and the risk of RB invasion in the 
univariate analyses, whereas no association was observed in the multivariate analyses (HR = 1.13, 95% 
CI = 0.68–1.88, P = 0.635, and HR = 1.38, 95% CI = 0.623–3.11, P = 0.431, respectively). However, no 
significant association was detected between the genotypes of the other two SNPs and the risk of RB 
invasion.
Moreover, a subgroup analysis of the association of p53 rs1042522 with RB invasion risk was per-
formed according to lag time and pre-enucleation treatment status. As shown in Table  4, in only the 
separate analyses of subgroups of lag time greater than 1 month and no prior treatment, the patients 
Variables
Total patients 
N = 168
Patients who 
received 
enucleation 
N = 131
Age at diagnosis (months)
 ≤ 12 months 64 (38.1) 42 (32.1)
 > 12 months 104 (61.9) 89 (67.9)
Gender
 Male 102 (60.7) 80 (61.1)
 Female 66 (39.3) 51 (38.9)
Family history of RB
 Absent 163 (97.0) 127 (96.9)
 Present 5 (3.0) 4 (3.1)
Lag time (months)
 Range (median) 0.0–48.0 (1.0) 0.0–48.0 (1.0)
 Mean ± SD 2.8 ± 5.8 3.0 ± 6.3
Laterality
 Unilateral 97 (57.7) 92 (70.2)
 Bilateral 71 (42.3) 39 (29.8)
Clinical predictors at presentation (eyes)
 Absent 171 (71.5) 78 (59.5)
 Present 68 (28.5) 53 (40.5)
Pre-enucleation treatment
 No prior treatment 96 (73.3)
 Systemic chemotherapy 
and/or focal treatmenta 35 (26.7)
Tumour invasion
 No invasion 37 (28.2)
 Moderate invasion 49 (37.4)
 High invasion 45 (34.4)
Table 1. Clinical characteristics of the patients with retinoblastoma. The results are shown as the 
frequencies and percentages unless otherwise indicated. aFocal treatment included periocular chemotherapy, 
laser photocoagulation, cryotherapy, or intra-arterial chemotherapy.
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exhibited a significantly increased EFS duration (P = 0.008, and P = 0.004, respectively) and reduced 
invasion risk (HR = 0.31, P = 0.007, and HR = 0.50, P = 0.010, respectively) for the GC carriers relative to 
the homozygous carriers. However, no significant association between the MDM2 or p21 genotypes and 
RB invasion was observed according to the subgroup analyses of lag time or pre-enucleation treatment 
(see Supplementary Table S3).
Figure 1. Typical raw data obtained using the Sequenom MassARRAY system for single nucleotide 
polymorphisms of (a–c) p53 rs1042522 G/C, (d–f) MDM2 rs2279744 T/G and (g–i) p21 rs1801270 C/A. The 
blue arrows above the wave peak indicate the resulting genotypes.
SNPs
Patients 
(n = 168)
Controls 
(n = 185)
OR (95% CI) Pa
HWE
n % n % pa,b
p53 rs1042522
 GG 53 31.5 52 28.1 1.00 (reference) 0.053
 GC 81 48.2 104 56.2 0.76 (0.47-1.24) 0.272 
 CC 34 20.2 29 15.7 1.15 (0.62-2.15) 0.661 
 C allele 44.3 43.8 1.02 (0.76-1.38) 0.881
MDM2 rs2279744
 TT 34 20.2 36 19.6 1.00 (reference) 0.715
 TG 75 44.6 88 47.8 0.90 (0.52-1.58) 0.720 
 GG 59 35.1 60 32.6 1.04 (0.58-1.88) 0.893
 T allele 42.6 43.5 0.96 (0.71-1.30) 0.806
p21 rs1801270
 CC 51 30.4 46 24.9 1.00 (reference) 0.712
 CA 81 48.2 95 51.4 0.77 (0.47-1.26) 0.300
 AA 36 21.4 44 23.8 0.74 (0.41-1.34) 0.316
 A allele 45.5 49.5 0.85 (0.64-1.15) 0.297
Table 2. Genotypic and allele frequencies of the selected SNPs in p53 pathway genes among patients and 
controls and the associations of these SNPs with the risk of retinoblastoma. Abbreviations: SNPs, single 
nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium. 
aP-value obtained from the Chi-squared test. bP-value obtained from Hardy-Weinberg equilibrium of the 
control group.
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Discussion
This study reports for the first time that the SNPs rs1042522, rs2279744, and rs1801270 in p53 pathway 
genes are not correlated with RB cancer risk, but rs1042522 is associated with RB invasion in a Chinese 
Han population. RB was classified according to the extent of tumour invasion to determine the associ-
ation of RB invasion with these SNPs. The heterozygous GC genotype of p53 rs1042522 was negatively 
associated with RB invasion among patients with a lag time greater than 1 month and among those who 
had not undergone pre-enucleation treatments; however, no associations were observed between MDM2 
rs2279744 or p21 rs1801270 and invasion.
Several studies have proposed a role for the p53 rs1042522 SNP as a risk factor for cancer due to its 
influence on cellular processes via p53-induced apoptosis33. Although the C allele frequency in Chinese 
RB (0.443) was relatively higher than that found in an Italian population (0.32) described in a previous 
report10, there was no association between the MAF of rs1042522 and RB cancer risk. This finding may 
be the result of a relatively high frequency of the C allele in the controls (0.438), which was similar to the 
C allele frequency of 0.489 in the Chinese population (HapMap-CHB database, http://hapmap.ncbi.nlm.
nih.gov). Additionally, no association between RB cancer risk and the rs1042522 genotypes was found in 
this study. This finding was not in agreement with a previous study, which found an association between 
the p53 CC genotype and hereditary RB among 111 patients in an Italian population10. At present, there 
is no mechanism to support any proposed role for the rs1042522 SNP as a risk factor for RB, and this 
lack of evidence may be due to conflicting results from different studies, which may also be attributed to 
the diverse distributions of SNPs in different races.
In addition, the mean age at presentation to our centre was 20.0 months, which was approximately 
the same as that in other Asian populations34–36. For the enucleated patients, those older than 12 months 
showed an increased risk of RB invasion based on univariate analysis (P = 0.001); this result was in 
Figure 2. Kaplan-Meier analysis of the association of the selected SNPs of p53 pathway genes with 
event-free survival (EFS) for RB invasion among enucleated patients. (a) Cumulative EFS curve of the 
enucleated patients for the three genotypes of p53 rs1042522 (P = 0.001 for GC versus GG, P = 0.914 for CC 
versus GG, and P = 0.003 for GC versus CC); (b) Cumulative EFS curve of enucleated patients according to 
the over-dominant genetic model of p53 rs1042522 (P = 0.000 for GC versus GG/CC). (c) Cumulative EFS 
curve of enucleated patients according to the three genotypes of MDM2 rs2279744 (P = 0.204 for TG versus 
TT, P = 0.265 for GG versus TT, and P = 0.940 for TG versus GG); (d) Cumulative EFS curve of enucleated 
patients according to the three genotypes of p21 rs1801270 (P = 0.524 for CA versus CC, P = 0.614 for AA 
versus CC, and P = 0.938 for CA versus AA).
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accord with a previous study showing that older age is strongly associated with a high risk of histopatho-
logical findings37, whereas age was correlated with pre-enucleation treatment status and lag time in our 
study. Meanwhile, our data are consistent with a previous finding that a relatively higher percentage of 
RB patients initially presented with unilateral RB34,36. The enucleated patients with bilateral RB exhibited 
Variable
No. of 
cases
No. of events 
(%)
Crude HR (95% 
CI) P
Adjusted HR (95% 
CI)a Pa
Age at presentation
 ≤ 12 months 42 24 (57.1) 1.00 (reference) 1.00 (reference)
 > 12 months 89 70 (78.7) 2.36 (1.45-3.83) 0.001 1.13 (0.68-1.88) 0.635 
Lag time
 ≤ 1 month 83 58 (69.9) 1.00 (reference) 1.00 (reference)
 > 1 month 45 34 (75.6) 0.47 (0.31-0.74) 0.001 0.10 (0.05-0.24) 0.000
Laterality
 Unilateral 93 73 (78.5) 1.00 (reference) 1.00 (reference)
 Bilateral 38 21 (55.3) 0.30 (0.18-0.50) 0.000 1.38 (0.62-3.11) 0.431
Pre-enucleation treatment
 No prior treatment 96 77 (80.2) 1.00 (reference) 1.00 (reference)
 Systemic chemotherapy and/or 
focal treatment 35 17 (48.6) 0.10 (0.05-0.20) 0.000 0.02 (0.004-0.05) 0.000 
p53 rs1042522
 GG/CC 72 56 (77.8) 1.00 (reference) 1.00 (reference)
 GC 59 38 (64.4) 0.46 (0.30-0.70) 0.000 0.53 (0.33-0.84) 0.007 
MDM2 rs2279744
 TT 31 22 (71.0) 1.00 (reference) 1.00 (reference)
 TG 58 45 (77.6) 1.40 (0.83-2.35) 0.204 1.04 (0.60-1.79) 0.888
 GG 42 27 (64.3) 1.37 (0.78-2.43) 0.277 0.91 (0.50-1.65) 0.755 
p21 rs1801270
 CC 39 30 (76.9) 1.00 (reference) 1.00 (reference)
 CA 65 46 (70.8) 0.87 (0.55-1.38) 0.560 1.20 (0.73, 1.95) 0.471 
 AA 27 18 (66.7) 0.88 (0.49-1.57) 0.654 0.82 (0.45-1.51) 0.522
Table 3.  Analyses of event-free survival for retinoblastoma invasion using a Cox proportional hazards 
model. Abbreviations: CI, confidence interval; HR, hazard ratio. aAdjusted for age, gender, laterality, clinical 
predictors, ICRB, lag time, and pre-enucleation treatment.
Genotype Subgroup
Log-rank analysisa Cox regression modelb
Time to RB invasion 
(median ± SE, 
months) P HR (95% CI) P
GG/CC Lag time ≤ 1 month 0.5 ± 0.1 1.00 (reference)
GC Lag time ≤ 1 month 5.6 ± 2.4 0.007 0.64 (0.35-1.15) 0.134
GG/CC Lag time > 1 month 5.0 ± 1.0 1.00 (reference)
GC Lag time > 1 month 8.0 ± 3.5 0.008 0.31 (0.13-0.73) 0.007
GG/CC No prior treatment 0.5 ± 0.2 1.00 (reference)
GC No prior treatment 3.0 ± 0.8 0.004 0.50 (0.30, 0.85) 0.010
GG/CC Pre-enucleation treatment 13.0 ± 1.0 1.00 (reference)
GC Pre-enucleation treatment 18.5 ± 6.0 0.587 0.25 (0.05, 1.14) 0.072
Table 4.  Subgroup analyses of the association between the p53 rs1042522 SNP and event-free survival 
for retinoblastoma invasion. Abbreviations: SNP, single nucleotide polymorphism; SE, standard error. 
aCrude analysis. bThe HRs and P values were adjusted for age, gender, laterality, clinical predictors, ICRB, lag 
time, and pre-enucleation treatment.
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a reduced risk of RB invasion in the univariate analysis (P = 0.000), whereas the patients with bilateral 
RB tended to require pre-enucleation treatment in our study. An explanation of these findings is that 
chemotherapy before the enucleation of eyes containing RB diminishes the pathologic characteristics of 
extraocular extension38, and the distribution of p53 rs1042522 genotypes was correlated with RB lateral-
ity, pre-enucleation treatment status, and lag time. For these reasons, the RB invasion risk was evaluated 
using multivariate analysis. After adjustment for clinical characteristics, the heterozygous genotype of 
p53 rs1042522 remained significantly associated with decreased RB invasion (P = 0.007).
Furthermore, subgroup analyses supported the association between the p53 rs1042522 GC genotype 
and RB invasion within the subgroup of patients with a lag time greater than 1 month (P = 0.007) or 
without prior treatment (P = 0.010). Therefore, an interaction between p53 rs1042522 genotypes and 
clinical characteristics (lag time and pre-enucleation treatment) contributed to RB invasion. This finding 
may be related to a decreased risk of future RB invasion because this result was observed in patients with 
a less invasive phenotype. These results may represent a “heterozygote advantage” situation in which the 
heterozygotes exhibit favourable survival characteristics39. Similar results have been observed in sickle 
cell anaemia40, HPV status in women from South Brazil,41 and breast cancer in an Iranian Azeri popula-
tion42. Therefore, our findings may be useful in the near future for the promotion of prevention strategies 
guided by the patient’s genotype because the p53 rs1042522 GC genotype was associated with reduced 
RB invasion (over-dominant model). However, contrary to our finding, the GC genotype of rs1042522 
showed a “heterozygote disadvantage” in which the heterozygote displayed an increased risk of metas-
tasis in breast-invasive ductal carcinoma, based on a study conducted in northeast Brazil43. Although 
two wild-type alleles of rs1042522 have different potentials in binding components of the transcrip-
tional machinery, activating transcription, inducing apoptosis, and repressing cancer cells, recent studies 
demonstrate that rs1042522 could also be associated with cancer through an epigenetic mechanism, 
including RNAi suppression44 and DNA methylation45. Thus, the exact biological and genetic mech-
anisms underlying such associations are uncertain, and further studies are necessary to confirm the 
association of the rs1042522 GC genotype with RB invasion.
Although the p53 gene is not mutated in primary RB46, the T-to-G variant of MDM2 has been shown 
to result in increased transcription, which plays a crucial role in the p53 pathway and in accelerating 
tumour formation21,47–50. The lack of an association of the MDM2 rs2279744 SNP contrasts with reports 
showing that the G allele appears to protect against RB development9,11. Moreover, our experiment did 
not show any association between the MDM2 rs2279744 SNP and RB invasion or the patients’ clinical 
characteristics. Thus, our findings appear to be plausible, considering a previous report showing that this 
association is only observed in p53-mutated cancers51.
Contrary to several molecular epidemiological studies that have reported the effects of the p21 
rs1801270 SNP on cancer risk, no increased risk of developing RB was found in the studied Chinese pop-
ulation (P = 0.712). This finding contradicted the increased RB risk shown in Brazilian carriers of the CA 
genotype13. Although the p21 rs1801270 A allele results in a 38% reduction of p21 mRNA expression52, 
we found no association between the rs1801270 SNP and RB invasion based on both univariate and mul-
tivariate analyses (adjusted or not adjusted for the clinical characteristics of the patients) of the overall 
data. These results may partly account for the variation in the data regarding the MAF of rs1801270 in 
the population, ranging from 4% in a Swedish population to 50% in a Chinese population53. Compared 
to the frequency of the A allele (21%) in RB patients, which was reported by Carvalho et al., a relatively 
high A allele frequency (45.5%) was found in our study.
In conclusion, we have demonstrated that the p53 rs1042522 GC genotype, but not the MDM2 
rs2279744 or p21 rs1801270 genotypes, is associated with a reduced risk of RB invasion in patients with 
a lag time greater than 1 month or in patients who received no prior treatment before enucleation, sug-
gesting an interaction of rs1042522 with lag time and pre-enucleation treatment status in RB invasion. 
Considering how these SNPs interact with germline mutations in the RB1 gene, the present findings—if 
validated in other populations—could provide novel therapeutic implications.
Methods
Ethics statement. This study was approved by the medical ethics committee of Zhongshan 
Ophthalmic Center in Guangzhou (No. 2013PRLL019). Additionally, informed consent was obtained 
from all individuals after a thorough explanation of the procedure and its risk in accordance with the 
principles of the Declaration of Helsinki.
Study population. A total of 168 RB patients and 185 cancer-free controls were included in the pres-
ent study. In brief, the patients were consecutively recruited from Zhongshan Ophthalmic Center of Sun 
Yat-sen University, Guangzhou, China, between February 2013 and October 2014. Unrelated controls of 
similar gender and ethnicity were recruited from healthy adults who visited the clinic for a general health 
check-up and had no individual history of cancer. Additionally, all subjects included in this study were 
Han Chinese. Subsequently, a peripheral blood sample was obtained from each recruited individual for 
genomic DNA extraction, and the clinical information about the RB patients (age at presentation, gender, 
family history of RB, lag time between first symptom and treatment onset, laterality, clinical predictors 
at presentation, ICRB classification54, therapeutic regimen (including chemotherapy, focal treatment and 
enucleation), histopathology reports, and duration between first symptom and enucleation onset) was 
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collected from their medical records. The included clinical predictors were glaucoma, pseudohypopyon, 
hyphaema, staphyloma, and neovascularisation of the iris37,55.
Assessment of RB invasion. The extent of tumour invasion into the anterior chamber, the iris, the 
ciliary body, the choroid, the sclera, the extra-scleral tissue, the optic nerve preceding or beyond the 
lamina, and the optic nerve section margin were recorded based on written pathology reports and were 
confirmed via a retrospective re-review of haematoxylin and eosin-stained slides. For some analyses, the 
enucleation group was further subdivided into the following three groups based on the AJCC pTNM 
stage of RB invasion: no (pT1), moderate (pT2), or high (pT3, pT4) tumour invasion56 (Table 5).
Laboratory methods. Total DNA extraction. Total genomic DNA was extracted from 100 μ L of 
EDTA-Na2 anticoagulated peripheral blood samples from each individual according to a previously 
described protocol57. The extracted DNA was eluted in 40 μ L of TE buffer and stored at − 20 °C in a 
dedicated area that was only used for PCR. The absorbance ratio of 260 nm to 280 nm was used to assess 
the purity of the isolated DNA using a Multiskan GO Microplate Spectrophotometer (Thermo Fisher 
Scientific, Inc., Waltham, MA, USA), and an absorbance ratio of ~1.8 was generally accepted as “pure”.
Genotyping. Based on the Sequenom Mass-ARRAY iPLEX platform, the SNP alleles were detected by 
allele-specific primer extension products using MALDI-TOF MS (Sequenom Inc., San Diego, California, 
USA). A multiplexed SNP assay was designed to test up to 3 SNPs using the “MySequenom” online 
design tools (https://www.mysequenom.com/Tools). According to the designated specifications, poly-
merase chain reaction (PCR) amplification primers and single-base extension (SBE) oligonucleotides 
for each SNP assay were synthesised and purified by Sangon Biotech Co., Ltd (Shanghai, China). PCR 
primers within the same multiplex were mixed at a final concentration of 1 μ M each, and the final con-
centrations of the SBE oligonucleotides were optimised according to the recommendations.
The genotyping reactions were performed on batches of 96-well plates according to the manufactur-
er’s instructions (http://www.sequenom.com). For PCR amplification, 10 ng of genomic DNA, dNTPs, 
primer mix, and HotStart Taq polymerase (Qiagen Inc., Valencia, CA) were added to each well, and 
the DNA was amplified via multiplex PCR. Unincorporated dNTPs present in the PCR product were 
neutralised using shrimp alkaline phosphatase (SAP), which was supplied with the iPLEX Gold rea-
gent kit (Sequenom Inc.). After the SAP reaction, the SBE reactions were performed by adding exten-
sion primers, DNA polymerase, and di-deoxynucleotide triphosphates (Sequenom Inc.) to each well. 
Subsequently, clean resin (Sequenom Inc.) was added to the mixture to remove extraneous salts that 
could interfere with MALDI-TOF analysis. The primer extension products were cleaned, and aliquots of 
each sample were dispensed onto a 96-pad SpectroCHIP (Sequenom Inc.). Ultimately, genotype calling 
Invasion 
grade Definition
No invasion
 pTX Primary tumour cannot be assessed
 pT0 No evidence of primary tumour
 pT1 Tumour confined to the eye, with no optic nerve or choroid invasion
Moderate invasion
 pT2a
Tumour superficially invades the optic nerve head 
but does not extend beyond the lamina cribrosa 
or exhibits focal choroidal invasion
 pT2b
Tumour superficially invades the optic nerve head 
but does not extend beyond the lamina cribrosa 
and exhibits focal choroidal invasion
High invasion
 pT3a
Tumour invades the optic nerve beyond the 
lamina cribrosa but not to the surgical resection 
line or exhibits massive choroidal invasion
 pT3b
Tumour invades the optic nerve beyond the 
lamina cribrosa but not to the surgical resection 
line and exhibits massive choroidal invasion
 pT4a Tumour invades the optic nerve to the resection line, but no extra-ocular extension is identified
 pT4b Tumour invades the optic nerve to the resection line, and extra-ocular extension is identified
Table 5.  The tumour invasion grade according to the T classification of pTNM.
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was performed in real time using MassARRAY RT software (version 3.0.0.4, Sequenom Inc.), and the 
results were analysed using MassARRAY Typer software (version 4.0, Sequenom Inc.). Duplicate samples 
and negative controls were included to verify the genotyping quality.
Statistical analysis. HWE of the genotype frequencies was tested using a goodness-of-fit Chi-square 
test with one degree of freedom among the controls. Comparisons of the SNPs between groups were ana-
lysed using Pearson’s Chi-square tests. Considering the major allele as the reference, logistic regression 
analysis was used to calculate the odds ratios (OR) and their corresponding 95% confidence intervals 
(CIs), which assessed the relative RB cancer risk conferred by each of the genotypes and alleles. In the 
univariate analysis, each genotype was independently analysed for a correlation with the duration of EFS 
for RB invasion. The Kaplan-Meier method was performed to estimate survival curves, and the log-rank 
test was used to compare the EFS duration between the subgroups of RB patients. In the multivariate 
analysis, the association between the genetic models of the selected SNPs and RB invasion risk was esti-
mated by computing the hazard ratio (HR) and the respective 95% CI using a Cox proportional hazards 
model, which was adjusted for potential risk factors that were significantly or marginally associated with 
invasion risk in the univariate analysis. If a P value was less than 0.05, the corresponding factor was 
included as a covariate in the Cox regression analysis. In the association analysis, all factors displaying 
P < 0.05 were subjected to subgroup analysis. All statistical tests were two-sided and were performed 
using SPSS version 20.0 for Mac OS (IBM Corporation, Armonk, New York, USA). The P value was set 
at a significance level of 0.05. For all multivariate analyses, the Bonferroni correction was applied.
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